Development of immunization trials against Klebsiella pneumoniae

Vaccine

Volumn 30, Issue 14, 2012, Pages 2411-2420

  Ahmad, Tarek A ^a   El Sayed, Laila H ^b   Haroun, Medhat ^a   Hussein, Ahmad A ^a   El Ashry, El Sayed H ^c  

^a ALEXANDRIA UNIVERSITY   (Egypt)

^b ALEXANDRIA UNIVERSITY   (Egypt)

^c Alexandria University Faculty Of Science   (Egypt)

Author keywords

Immunotherapy; Klebsiella pneumoniae; Vaccine

Indexed keywords

BACTERIAL PROTEIN; FIMBRIA PROTEIN; OUTER MEMBRANE PROTEIN; POLYSACCHARIDE VACCINE;

ACTIVE IMMUNIZATION; ANTIBIOTIC RESISTANCE; BACTERIAL COLONIZATION; CRANBERRY JUICE; EPIDEMIC; HOSPITAL INFECTION; HUMAN; IMMUNIZATION; IMMUNOTHERAPY; INCIDENCE; INFECTION CONTROL; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; REVIEW;

EID: 84975801859     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.11.027     Document Type: Review

References (140)

1. Edberg S.C., Piscitelli V., Cartter M. Phenotypic characteristics of coliform and noncoliform bacteria from a public water supply compared with regional and national clinical species. Appl Environ Microbiol 1986, 52:474-478.
2. Bagley S.T., Seidler R.J., Talbot H.W., Morrow J.E. Isolation of Klebsielleae from within living wood. Appl Environ Microbiol 1978, 36:178-185.
3. Seidler R.J., Knittel M.D., Brown C. Potential pathogens in the environment: cultural reactions and nucleic acid studies on Klebsiella pneumoniae from clinical and environmental sources. Appl Microbiol 1975, 29:819-825.
4. Matsen J.M., Spindler J.A., Blosser R.O. Characterization of Klebsiella isolates from natural receiving waters and comparison with human isolates. Appl Microbiol 1974, 28:672-678.
5. Brown C., Seidler R.J. Potential pathogens in the environment: Klebsiella pneumoniae, a taxonomic and ecological enigma. Appl Microbiol 1973, 25:900-904.
6. Schwaber M.J., Navon-Venezia S., Kaye K.S., Ben-Ami R., Schwartz D., Carmeli Y. Clinical and economic impact of bacteremia with extended-spectrum-β-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2006, 50:1257-1262.
7. Montgomerie J.Z. Epidemiology of Klebsiella and hospital-associated infections. Rev Infect Dis 1979, 1:736-753.
8. Kim Y.K., Pai H., Lee H.J., Park S.E., Choi E.H., Kim J., et al. Bloodstream infections by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrob Agents Chemother 2002, 46:1481-1491.
9. Podschun R., Ullmann U. Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. Clin Microbiol Rev 1998, 11:589-603.
10. Merino S., Camprubí S., Albertí S., Benedí V.J., Tomás J.M. Mechanisms of Klebsiella pneumoniae resistance to complement-mediated killing. Infect Immun 1992, 60:2529-2535.
11. Centers for Disease Control (CDC). National nosocomial infections study report. Annual summary 1975. Atlanta, GA: Centers for Disease Control; 1977.
12. Matsen J.M. The sources of hospital infection. Medicine (Baltimore) 1973, 52:271-277.
13. Selden R., Lee S., Wang W.L., Bennett J.V., Eickhoff T.C. Nosocomial Klebsiella infections: intestinal colonization as a reservoir. Ann Intern Med 1971, 74:657-664.
14. Doebbeling B.N. Epidemics: identification and management. Prevention and control of nosocomial infections 1993, 177-206. The Williams & Wilkins Co., Baltimore, MD. R.P. Wenzel (Ed.).
15. Bryan C.S., Reynolds K.L., Brenner E.R. Analysis of 1,186 episodes of gram-negative bacteraemia in non-university hospitals: the effects of antimicrobial therapy. Rev Infect Dis 1983, 5:629-638.
16. Young L.S. Nosocomial infections in the immunocompromised adult. Am J Med 1981, 70:398-404.
17. McGowan J.E., Barnes M.W., Finland M. Bacteraemia at Boston City Hospital: occurrence and mortality during 12 selected years (1935-1972), with special reference to hospital-acquired cases. J Infect Dis 1975, 132:316-335.
18. Graybill J.R., Marshall L.W., Charache P., Wallace C.K., Melvin V.B. Nosocomial pneumonia. A continuing major problem. Am Rev Respir Dis 1973, 108:1130-1140.
19. Coovadia Y.M., Johnson A.P., Bhana R.H., Hutchinson G.R., George R.C., Hafferjee I.E. Multiresistant Klebsiella pneumoniae in a neonatal nursery: the importance of maintenance of infection control policies and procedures in the prevention of outbreaks. J Hosp Infect 1992, 22:197-205.
20. Hart C.A. Klebsiella and neonates. J Hosp Infect 1993, 23:83-86.
21. Rice L.B., Willey S.H., Papanicolaou G.A., Medeiros A.A., Eliopoulos G.M., Moellering R.C., et al. Outbreak of ceftazidime resistance caused by extended-spectrum beta-lactamases at a Massachusetts chronic-care facility. Antimicrob Agents Chemother 1990, 34:2193-2199.
22. Ernst J.D. Toward the development of antibacterial vaccines: report of a symposium and workshop. Organizing committee. Clin Infect Dis 1999, 29:1295-1302.
23. Girlich D., Karim A., Poirel L., Cavin M.H., Verny C., Nordmann P. Molecular epidemiology of an outbreak due to IRT-2 β-lactamse-producing strains of Klebsiella pneumoniae in a geriatric department. J Antimicrob Chemother 2000, 45:467-473.
24. Knothe H., Shah P., Krcmery V., Antal M., Mitsuhashi S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 1983, 11:315-317.
25. Pai H., Kang C.I., Byeon J.H., Lee K.D., Park W.B., Kim H.B., et al. Epidemiology and clinical features of bloodstream infections caused by AmpC-type-β-lactamase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2004, 48:3720-3728.
26. Bradford P.A. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001, 14:933-951.
27. Nordmann P. Trends in β-lactam resistance among Enterobacteriaceae. Clin Infect Dis 1998, 27:S100-S106.
28. Medeiros A.A. Evolution and dissemination of beta-lactamases accelerated by generations of beta-lactam antibiotics. Clin Infect Dis 1997, 24:S19-S45.
29. Sirot D., Sirot J., Labia R., Morand A., Courvalin P., Darfeuille-Michaud A., et al. Transferable resistance to third-generation cephalosporins in clinical isolates of Klebsiella pneumoniae: identification of CTX-1, a novel β-lactamase. J Antimicrob Chemother 1987, 20:323-334.
30. Kliebe C., Nies B.A., Meyer J.F., Tolxdorff-Neutzling R.M., Wiedemann B. Evolution of plasmid-coded resistance to broad-spectrum cephalosporins. Antimicrob Agents Chemother 1985, 28:302-307.
31. Jarlier V., Nicolas M.H., Fournier G., Philippon A. Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis 1988, 10:867-878.
32. Bingen E.H., Desjardins P., Arlet G., Bourgeois F., Mariani-Kurkdjian P., Lambert-Zechovsky N.Y., et al. Molecular epidemiology of plasmid spread among extended broad-spectrum beta-lactamase-producing Klebsiella pneumoniae isolates in a pediatric hospital. J Clin Microbiol 1993, 31:179-184.
33. Valverde A., Coque T.M. García-San Miguel L, Baquero F, Cantón R. Complex molecular epidemiology of extended-spectrum beta-lactamases in Klebsiella pneumoniae: a long-term perspective from a single institution in Madrid. J Antimicrob Chemother 2008, 61:64-72.
34. Ostroff S.M., Harrison L.H., Khallaf N., Assaad M.T., Guirguis N.I., Harrington S., et al. Resistance patterns of Streptococcus pneumoniae and Haemophilus influenzae isolates recovered in Egypt from children with pneumonia. The Antimicrobial Surveillance Study Group. Clin Infect Dis 1996, 23:1069-1074.
35. Peña C., Pujol M., Ardanuy C., Ricart A., Pallares R., Liñares J., et al. Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother 1998, 42:53-58.
36. Gillis S., Dann E.J., Berkman Y., Koganox N., Kramer M.R. Fatal Haemophilus influenzae septicemia following bronchoscopy in a splenectomized patient. Chest 1993, 104:1607-1609.
37. Alobwede I., M'Zali F.H., Livermore D.M., Heritage J., Todd N., Hawkey P.M. CTX-M extended-spectrum beta-lactamase arrives in the UK. J Antimicrob Chemother 2003, 51:470-471.
38. Mulvey M.R., Bryce E., Boyd D., Ofner-Agostini M., Christianson S., Simor A.E., et al. Ambler class A extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. in Canadian hospitals. Antimicrob Agents Chemother 2004, 48:1204-1214.
39. Chanawong A., M'Zali F.H., Heritage J., Xiong J.H., Hawkey P.M. Three cefotaximases, CTX-M-9, CTX-M-13, and CTX-M-14, among Enterobacteriaceae in the People's Republic of China. Antimicrob Agents Chemother 2002, 46:630-637.
40. Pai H., Choi E.H., Lee H.J., Hong J.Y., Jacoby G.A. Identification of CTX-M-14 extended-spectrum beta-lactamase in clinical isolates of Shigella sonnei, Escherichia coli, and Klebsiella pneumoniae in Korea. J Clin Microbiol 2001, 39:3747-3749.
41. Bratu S., Landman D., Haag R., Recco R., Eramo A., Alam M., et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch Intern Med 2005, 165:1430-1435.
42. Landman D., Quale J.M., Mayorga D., Adedeji A., Vangala K., Ravishankar J., et al. Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: the preantibiotic era has returned. Arch Intern Med 2002, 162:1515-1520.
43. Martin C.M., Ikari N.S., Zimmerman J., Waitz J.A. A virulent nosocomial Klebsiella with a transferable R factor for gentamicin: emergence and suppression. J Infect Dis 1971, 124:S24-S29.
44. Yagi T., Kurokawa H., Shibata N., Shibayama K., Arakawa Y. A preliminary survey of extended-spectrum beta-lactamases (ESBLs) in clinical isolates of Klebsiella pneumoniae and Escherichia coli in Japan. FEMS Microbiol Lett 2000, 184:53-56.
45. Baraniak A., Fiett J., Sulikowska A., Hryniewicz W., Gniadkowski M. Countrywide spread of CTX-M-3 extended-spectrum beta-lactamase-producing microorganisms of the family Enterobacteriaceae in Poland. Antimicrob Agents Chemother 2002, 46:151-159.
46. Edelstein M., Pimkin M., Palagin I., Edelstein I., Stratchounski L. Prevalence and molecular epidemiology of CTX-M extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Russian hospitals. Antimicrob Agents Chemother 2003, 47:3724-3732.
47. Soge O.O., Adeniyi B.A., Roberts M.C. New antibiotic resistance genes associated with CTX-M plasmids from uropathogenic Nigerian Klebsiella pneumoniae. J Antimicrob Chemother 2006, 58:1048-1053.
48. Shearer M.J., Bechtold H., Andrassy K., Koderisch J., McCarthy P.T., Trenk D., et al. Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status. J Clin Pharmacol 1988, 28:88-95.
49. Kitson T.M. The effect of cephalosporin antibiotics on alcohol metabolism: a review. Alcohol 1987, 4:143-148.
50. Breecher M.M. IDSA: Achilles tendon rupture after use of antibiotics 2007, Doctor's Guide, San Diego, CA. Global ed.
51. Klein R.D., Edberg S.C. Applications, significance of, and methods for the measurement of antimicrobial concentrations in human body fluids. Antibiotics in laboratory medicine 2005, 290-364. Lippincott Williams & Wilkins, Orlando, FL. V. Lorian (Ed.).
52. Hsueh P.R., Liu C.Y., Luh K.T. Current status of antimicrobial resistance in Taiwan. Emerg Infect Dis 2002, 8:132-137.
53. Yu W.L., Jones R.N., Hollis R.J., Messer S.A., Biedenbach D.J., Deshpande L.M., et al. Molecular epidemiology of extended-spectrum beta-lactamase-producing, fluoroquinolone-resistant isolates of Klebsiella pneumoniae in Taiwan. J Clin Microbiol 2002, 40:4666-4669.
54. Hardy D.J., Legeai R.J., O'Callaghan R.J. Klebsiella neonatal injections: mechanism of broadening aminoglycoside resistance. Antimicrob Agents Chemother 1980, 18:542-548.
55. Yan J.J., Wu J.J., Ko W.C., Tsai S.H., Chuang C.L., Wu H.M., et al. Plasmid-mediated 16S rRNA methylases conferring high-level aminoglycoside resistance in Escherichia coli and Klebsiella pneumoniae isolates from two Taiwanese hospitals. J Antimicrob Chemother 2004, 54:1007-1012.
56. Ofek I., Goldhar J., Zafriri D., Lis H., Adar R., Sharon N. Anti-Escherichia coli adhesin activity of cranberry and blueberry juices. N Engl J Med 1991, 324:1599-1602.
57. Avorn J., Monane M., Gurwitz J.H., Glynn R.J., Choodnovskiy I., Lipsitz L.A. Reduction of bacteriuria and pyuria after ingestion of cranberry juice. JAMA 1994, 271:751-754.
58. Cryz S.J. Progress in immunization against Klebsiella infections. Eur J Clin Microbiol 1983, 2:523-528.
59. Laichalk L.L., Kunkel S.L., Strieter R.M., Danforth J.M., Bailie M.B., Standiford T.J. Tumor necrosis factor mediates lung antibacterial host defense in murine Klebsiella pneumonia. Infect Immun 1996, 64:5211-5218.
60. Karaolis D.K., Newstead M.W., Zeng X., Hyodo M., Hayakawa Y., Bhan U., et al. Cyclic di-GMP stimulates protective innate immunity in bacterial pneumonia. Infect Immun 2007, 75:4942-4950.
61. Cooper J.M., Rowley D. Resistance to Klebsiella pneumoniae and the importance of two bacterial antigens. Aust J Exp Biol Med Sci 1982, 60:629-641.
62. Weller T.M., MacKenzie F.M., Forbes K.J. Molecular epidemiology of a large outbreak of multiresistant Klebsiella pneumoniae. J Med Microbiol 1997, 46:921-926.
63. Ben-Hamouda T., Foulon T., Ben-Cheikh-Masmoudi A., Fendri C., Belhadj O., Ben-Mahrez K. Molecular epidemiology of an outbreak of multiresistant Klebsiella pneumoniae in a Tunisian neonatal ward. J Med Microbiol 2003, 52:427-433.
64. Prodinger W.M., Fille M., Bauernfeind A., Stemplinger I., Amann S., Pfausler B., et al. Molecular epidemiology of Klebsiella pneumoniae producing SHV-5 beta-lactamase: parallel outbreaks due to multiple plasmid transfer. J Clin Microbiol 1996, 34:564-568.
65. Carrigan S.D., Scott G., Tabrizian M. Toward resolving the challenges of sepsis diagnosis. Clin Chem 2004, 50:1301-1314.
66. Greenberger M.J., Kunkel S.L., Strieter R.M., Lukacs N.W., Bramson J., Gauldie J., et al. IL-12 gene therapy protects mice in lethal Klebsiella pneumonia. J Immunol 1996, 157:3006-3012.
67. Riottot M., Fournier J.M., Pillot J. Capsular serotypic specificity of the protection conferred on mice by Klebsiella pneumoniae ribosomal preparations. Infect Immun 1979, 24:476-482.
68. Riottot M.M., Fournier J.M., Jouin H. Direct evidence for the involvement of capsular polysaccharide in the immunoprotective activity of Klebsiella pneumoniae ribosomal preparations. Infect Immun 1981, 31:71-77.
69. Fournier J.M., Jolivet-Reynaud C., Riottot M.M., Jouin H. Murine immunoprotective activity of Klebsiella pneumoniae cell surface preparations: comparative study with ribosomal preparations. Infect Immun 1981, 32:420-426.
70. Cryz S.J., Fürer E., Germanier R. Protection against fatal Klebsiella pneumoniae burn wound sepsis by passive transfer of anticapsular polysaccharide. Infect Immun 1984, 45:139-142.
71. Cryz S.J., Fürer E., Germanier R. Prevention of fatal experimental burn-wound sepsis due to Klebsiella pneumoniae KP1-O by immunization with homologous capsular polysaccharide. J Infect Dis 1984, 150:817-822.
72. Cryz S.J., Fürer E., Germanier R. Safety and immunogenicity of Klebsiella pneumoniae K1 capsular polysaccharide vaccine in humans. J Infect Dis 1985, 151:665-671.
73. Cryz S.J., Fürer E., Germanier R. Purification and vaccine potential of Klebsiella capsular polysaccharides. Infect Immun 1985, 50:225-230.
74. Roe E.A., Jones R.J., Dyster R.E. Passive immunization of mice against Klebsiella aerogenes. Br J Exp Pathol 1986, 67:25-32.
75. Trautmann M., Cryz S.J., Sadoff J.C., Cross A.S. A murine monoclonal antibody against Klebsiella capsular polysaccharide is opsonic in vitro and protects against experimental Klebsiella pneumoniae infection. Microb Pathog 1988, 5:177-187.
76. Held T.K., Trautmann M., Mielke M.H., Neudeck H., Cryz S.J., Cross A.S. Monoclonal antibody against Klebsiella capsular polysaccharide reduces severity and hematogenic spread of experimental Klebsiella pneumoniae pneumonia. Infect Immun 1992, 60:1771-1778.
77. Donta S.T., Peduzzi P., Cross A.S., Sadoff J., Haakenson C., Cryz S.J., et al. Immunoprophylaxis against Klebsiella and Pseudomonas aeruginosa infections. The Federal Hyperimmune Immunoglobulin Trial Study Group. J Infect Dis 1996, 174:537-543.
78. Trautmann M., Vogt K., Hammack C., Cross A.S. A murine monoclonal antibody defines a unique epitope shared by Klebsiella lipopolysaccharides. Infect Immun 1994, 62:1282-1288.
79. van der Meer N.M., Appelmelk B.J., Verweij-can Vught A.M., Nimmich W., Kosma P., Thijs L.G., et al. Binding studies of a monoclonal antibody specific for 3-deoxy-d-manno-octulosonic acid with a panel of Klebsiella pneumoniae lipopolysaccharides representing all of the O serotypes. Infect Immun 1994, 62:1052-1057.
80. Rukavina T., Ticac B., Susa M., Jendrike N., Jonjíc S., Lucin P., et al. Protective effect of antilipopolysaccharide monoclonal antibody in experimental Klebsiella infection. Infect Immun 1997, 65:1754-1760.
81. Hackett R.J., Marcus S. Extent of specific to nonspecific resistance in mice: parenteral versus aerosol challenge. Infect Immun 1970, 1:274-278.
82. Green J.H., Pigott N.E., Bolin R.C., Harrell W.K. Use of acetone-dried vaccines for preparing capsular antisera against the Klebsiella group and the lyophilization of Klebsiella cultures. Appl Microbiol 1970, 20:416-420.
83. Kurbatova E.A., Egorova N.B., Kiseleva B.S. Protective activity of a cell-free Klebsiella vaccine in relation to different Klebsiella pneumoniae serovars. Zh Mikrobiol Epidemiol Immunobiol 1984, 8:80-83. [article in Russian].
84. Kurbatova E.A., Lazareva E.S., Gladus M.A. Effect of a hydroxylamine Klebsiella vaccine on the rate of elimination of the causative agent and on indices of humoral immunity. Zh Mikrobiol Epidemiol Immunobiol 1988, 9:75-79. [article in Russian].
85. Shagam N.L., Efremova V.N., Kurbatova E.A., Kaverina K.G. Chemical and immunochemical characteristics of antigenic preparations from Staphylococcus aureus and Klebsiella pneumoniae as the components for an associated vaccine. Zh Mikrobiol Epidemiol Immunobiol 1988, 6:51-55. [article in Russian].
86. Kurbatova E.A., Egorova N.B., Dubova V.G., Davatdarova G.M., Lipats A.A., Gervazieva V.B., et al. The reactogenicity and immunological efficacy of a Klebsiella vaccine in donors. Zh Mikrobiol Epidemiol Immunobiol 1990, 5:53-56. [article in Russian].
87. Mansurova N.L., Egorova N.B., Kaverina K.G., Poliachenko V.M., Lobova E.A. The specific activity of a multicomponent vaccine made from the antigens of opportunistic microorganisms. Zh Mikrobiol Epidemiol Immunobiol 1991, 4:39-41. [article in Russian].
88. Miriasova L.V., Efimtseva O.V., Karabak I.V., Basnak'ian I.A., Egorova N.B. The fractional composition of hydroxylamine preparations and of the lipopolysaccharide of a vaccinal strain of Klebsiella pneumoniae. Zh Mikrobiol Epidemiol Immunobiol 1997, 3:73-76. [article in Russian].
89. Straus D.C. Production of an extracellular toxic complex by various strains of Klebsiella pneumoniae. Infect Immun 1987, 55:44-48.
90. Kuenen J.D., van Dijke E.E., Hol C., Bootsma H.J., Verhoef J., van Dijk H. Protective effects of orally administered, Klebsiella-containing bacterial lysates in mice. FEMS Immunol Med Microbiol 1994, 8:69-75.
91. Michel F.B., D'Hinterland L.D., Bousquet J., Pinel A.M., Normier G. Immuno-stimulation by a ribosomal vaccine associated with a bacterial cell wall adjuvant in humans. Infect Immun 1978, 20:760-769.
92. Riottot M.M., Fournier J.M. Immunoprotective activity of capsular polysaccharide in Klebsiella pneumoniae ribosomal preparations does not involve ribonucleic acid. Infect Immun 1981, 34:126-130.
93. Klipstein F.A., Engert R.F., Houghten R.A. Immunological properties of purified Klebsiella pneumoniae heat-stable enterotoxin. Infect Immun 1983, 42:838-841.
94. Singh B.R., Sharma V.D. Potential of Klebsiella pneumoniae cytotoxin toxoid as vaccine against klebsiellosis in rabbits and mice. Vaccine 2001, 19:4505-4510.
95. Witkowska D., Mieszala M., Czamy A., Kübler J., Gamian A., Przondo-Mordarska A., et al. A new type of glycoconjugate vaccine containing Klebsiella fimbriae type 1 and 3 as carrier proteins. Crit Care 1997, 1. PO34-20.
96. Lavender H., Jagnow J.J., Clegg S. Klebsiella pneumoniae type 3 fimbria-mediated immunity to infection in the murine model of respiratory disease. Int J Med Microbiol 2005, 295:153-159.
97. Serushago B.A., Mitsuyama M., Handa T., Koga T., Nomoto K. Role of antibodies against outer-membrane proteins in murine resistance to infection with encapsulated Klebsiella pneumoniae. J Gen Microbiol 1989, 135:2259-2268.
98. Rauly I., Goetsch L., Haeuw J.F., Tardieux C., Baussant T., Bonnefoy J.Y., et al. Carrier properties of a protein derived from outer membrane protein A of Klebsiella pneumoniae. Infect Immun 1999, 67:5547-5551.
99. Goetsch L., Gonzalez A., Plotnicky-Gilquin H., Haeuw J.F., Aubry J.P., Beck A., et al. Targeting of nasal mucosa-associated antigen-presenting cells in vivo with an outer membrane protein A derived from Klebsiella pneumoniae. Infect Immun 2001, 69:6434-6444.
100. Kurupati P., Ramachandran N.P., Poh C.L. Protective efficacy of DNA vaccines encoding outer membrane protein A and OmpK36 of Klebsiella pneumoniae in mice. Clin Vaccine Immunol 2011, 18(1):82-88.
101. Cryz S.J., Mortimer P.M., Mansfield V., Germanier R. Seroepidemiology of Klebsiella bacteremic isolates and implications for vaccine development. J Clin Microbiol 1986, 23:687-690.
102. Smith S.M., Digori J.T., Eng R.H. Epidemiology of Klebsiella antibiotics resistance and serotypes. J Clin Microbiol 1982, 16:868-873.
103. Camprubí S., Merino S., Guillot J.F., Tomás J.M. The role of the O-antigen lipopolysaccharide on the colonization in vivo of the germfree chicken gut by Klebsiella pneumoniae. Microb Pathog 1993, 14:433-440.
104. Camprubí S., Merino S., Benedí V.J., Tomás J.M. The role of the O-antigen lipopolysaccharide and capsule on an experimental Klebsiella pneumoniae infection of the rat urinary tract. FEMS Microbiol Lett 1993, 111:9-13.
105. Jenney A.W., Clements A., Farn J.L., Wijburg O.L., McGlinchey A., Spelman D.W., et al. Seroepidemiology of Klebsiella pneumoniae in an Australian tertiary hospital and its implications for vaccine development. J Clin Microbiol 2006, 44:102-107.
106. Hansen D.S., Mestre F., Alberti S., Hernández-Allés S., Alvarez D., Doménech-Sánchez A., et al. Klebsiella pneumoniae lipo-polysaccharide O typing: revision of prototype strains and O-group distribution among clinical isolates from different sources and countries. J Clin Microbiol 1999, 37:56-62.
107. Fung C.P., Hu B.S., Chang F.Y., Lee S.C., Kuo B.I., Ho M., et al. A 5-year study of the seroepidemiology of Klebsiella pneumoniae: high prevalence of capsular serotype K1 in Taiwan and implication for vaccine efficacy. J Infect Dis 2000, 181:2075-2079.
108. Trautmann M., Ruhnke M., Rukavina T., Held T.K., Cross A.S., Marre R., et al. O-antigen seroepidemiology of Klebsiella clinical isolates and implications for immunoprophylaxis of Klebsiella infections. Clin Diagn Lab Immunol 1997, 4:550-555.
109. Jones R.J., Roe E.A. Vaccination against 77 capsular types of Klebsiella aerogenes with polyvalent Klebsiella vaccines. J Med Microbiol 1984, 18:413-421.
110. Roe E.A., Jones R.J. Vaccination against Klebsiella aerogenes. J Hyg (Lond) 1984, 93:355-363.
111. Roe E.A., Jones R.J., Saunders J.R. Immunoprotective extracellular polysaccharides of Klebsiella aerogenes capsular type K1, expressed in Escherichia coli. FEMS Microbiol Immunol 1989, 1:253-261.
112. Robert A., Jouin H., Fournier J.M. Immunogenic properties of Klebsiella pneumoniae type 2 capsular polysaccharide. Infect Immun 1986, 54:365-370.
113. Postal J.M., Gysin J., Crenn Y. Protection against fatal Klebsiella pneumoniae sepsis in the squirrel monkey Saimiri sciureus after immunization with a capsular polysaccharide vaccine. Ann Inst Pasteur Immunol 1988, 139:401-407.
114. Alcántar-Curiel M.D., Martínez-Ramos A., García-Latorre E. Capsular polysaccharide of Klebsiella pneumoniae. II. Immunogenic properties. Rev Latinoam Microbiol 1993, 35:109-115. [article in Spanish].
115. Cryz S.J., Fürer E., Germanier R. Immunization against fatal experimental Klebsiella pneumoniae pneumonia. Infect Immun 1986, 54:403-407.
116. Cryz S.J., Mortimer P., Cross A.S., Fürer E., Germanier R. Safety and immunogenicity of a polyvalent Klebsiella capsular polysaccharide vaccine in humans. Vaccine 1986, 4:15-20.
117. Granström M., Wretlind B., Markman B., Cryz S. Enzyme-linked immunosorbent assay to evaluate the immunogenicity of a polyvalent Klebsiella capsular polysaccharide vaccine in humans. J Clin Microbiol 1988, 26:2257-2261.
118. Cryz S.J., Cross A.S., Sadoff G.C., Que J.U. Human IgG and IgA subclass response following immunization with a polyvalent Klebsiella capsular polysaccharide vaccine. Eur J Immunol 1988, 18:2073-2075.
119. Cross A.S., Sadoff J.C., Furer E., Cryz S.J. Escherichia coli and Klebsiella vaccines and immunotherapy. Infect Dis Clin North Am 1990, 4:271-282.
120. Edelman R., Taylor D.N., Wasserman S.S., McClain J.B., Cross A.S., Sadoff J.C., et al. Phase 1 trial of a 24-valent Klebsiella capsular polysaccharide vaccine and an eight-valent Pseudomonas O-polysaccharide conjugate vaccine administered simultaneously. Vaccine 1994, 12:1288-1294.
121. Campbell W.N., Hendrix E., Cryz S.J., Cross A.S. Immunogenicity of a 24-valent Klebsiella capsular polysaccharide vaccine and an eight-valent Pseudomonas O-polysaccharide conjugate vaccine administered to victims of acute trauma. Clin Infect Dis 1996, 23:179-181.
122. Lüderitz O., Staub A.M., Westphal O. Immunochemistry of O and R antigens of Salmonella and related Enterobacteriaceae. Bacteriol Rev 1966, 30:192-255.
123. Bennett-Guerrero E., McIntosh T.J., Barclay G.R., Snyder D.S., Gibbs R.J., Mythen M.G., et al. Preparation and preclinical evaluation of a novel liposomal complete-core lipopolysaccharide vaccine. Infect Immun 2000, 68:6202-6208.
124. Chhibber S., Wadhwa S., Yadav V. Protective role of liposome incorporated lipopolysaccharide antigen of Klebsiella pneumoniae in a rat model of lobar pneumonia. Jpn J Infect Dis 2004, 57:150-155.
125. Tomás J.M., Camprubí S., Merino S., Davey M.R., Williams P. Surface exposure of O1 serotype lipopolysaccharide in Klebsiella pneumoniae strains expressing different K antigens. Infect Immun 1991, 59:2006-2011.
126. Tomás J.M., Camprubí S., Williams P. Surface exposure of the O-antigen in Klebsiella pneumoniae O1:K1 serotype strains. Microb Pathog 1988, 5:141-147.
127. Tomás J.M., Benedí V.J., Ciurana B., Fofre J. Role of capsule and O antigen in resistance of Klebsiella pneumoniae to serum bactericidal activity. Infect Immun 1986, 54:85-89.
128. Williams P., Lambert P.A., Brown M.R. Penetration of immunoglobulins through the Klebsiella capsule and their effect on cell-surface hydrophobicity. J Med Microbiol 1988, 26:29-35.
129. Meno Y., Amako K. Morphological evidence for penetration of anti-O antibody through the capsule of Klebsiella pneumoniae. Infect Immun 1990, 58:1421-1428.
130. Ahmad T. Construction and evaluation of a conjugate vaccine for the prevention of sepeticemia [PhD]. Alexandria: Alexandria University; 2011.
131. Mandine E., Salles M.F., Zalisz R., Guenounou M., Smets P. Murine monoclonal antibodies to Klebsiella pneumoniae protect against lethal endotoxemia and experimental infection with capsulated K. pneumoniae. Infect Immun 1990, 58:2828-2833.
132. Yokochi T., Inoue Y., Kato Y., Sugiyama T., Jiang G.Z., Kawai M., et al. Strong adjuvant action of Klebsiella O3 lipopolysaccharide and its inhibition of systemic anaphylaxis. FEMS Immunol Med Microbiol 1995, 10:181-184.
133. Cross A.S. Development of an anti-endotoxin vaccine for sepsis. Subcell Biochem 2010, 53:285-302.
134. Yadav V., Sharma S., Harjai K., Mohan H., Chhibber S. Lipopolysaccharide-mediated protection against Klebsiella pneumoniae-induced lobar pneumonia: intranasal vs. intramuscular route of immunization. Folia Microbiol (Praha) 2005, 50:83-86.
135. Clements A., Jenney A.W., Farn J.L., Brown L.E., Deliyannis G., Hartland E.L., et al. Targeting subcapsular antigens for prevention of Klebsiella pneumoniae infections. Vaccine 2008, 26:5649-5653.
136. Zigterman J.W., Van-Dam J.E., Snippe H., Rotteveel F.T., Jansze L., Willers J.M., et al. Immunogenic properties of octasaccharide-protein conjugates derived from Klebsiella serotype 11 capsular polysaccharide. Infect Immun 1985, 47:421-428.
137. Chhibber S., Bajaj J. Polysaccharide-iron-regulated cell surface protein conjugate vaccine: its role in protection against Klebsiella pneumoniae-induced lobar pneumonia. Vaccine 1995, 13:179-184.
138. Chhibber S., Rani M., Vanashree Y. Immunoprotective potential of polysaccharide-tetanus toxoid conjugate in Klebsiella pneumoniae induced lobar pneumonia in rats. Indian J Exp Biol 2005, 43:40-45.
139. Caroff M.G., Karibian D. Several uses for isobutyric acid-ammonium hydroxide solvent in endotoxin analysis. Appl Environ Microbiol 1990, 56:1957-1959.
140. Fisher C.J., Agosti J.M., Opal S.M., Lowry S.F., Balk R.A., Sadoff J.C., et al. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996, 334:1697-1702.